1. US Food and Drug Administration. FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC. fda.gov, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc (2021).
2. Zhao, D., Liu, Y., Yi, F., Zhao, X. & Lu, K. Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways. Eur. J. Med. Chem. 259, 115698 (2023).
3. US Food and Drug Administration. FDA Briefing Document: Oncologic Drugs Advisory Committee Meeting, October 5, 2023. NDA 214665 s005, Sotorasib; Amgen, Inc. (FDA, 2023).
4. Amgen, Inc. Background Information for the Oncologic Drugs Advisory Committee. 05 October 2023. Supplemental New Drug Application for Sotorasib (Amgen Inc., 2023).
5. Amgen. Amgen provides regulatory update on status of lumakras (sotorasib). PR Newswire, https://www.prnewswire.com/news-releases/amgen-provides-regulatory-update-on-status-of-lumakras-sotorasib-302022131.html (2023).